Conflicting statements and intense ethical debate surround a controversial clinical study testing the effects of the hepatitis B vaccine on newborns in Guinea-Bissau. While representatives from the Africa Centres for Disease Control and Prevention (CDC) stated that the disputed project had been canceled, U.S. health officials have contested that claim, maintaining that the research is moving forward.
Details of the Guinea-Bissau Vaccine Trial
The controversy stems from a $1.6 million, five-year federal grant awarded by the U.S. Centers for Disease Control and Prevention (CDC) to the Bandim Health Project at the University of Southern Denmark. Administered to fund the HBV0-NSE trial, the project intends to enroll approximately 14,000 newborns in Guinea-Bissau in West Africa.
The randomized controlled study aims to examine early-life mortality, morbidity, and long-term developmental outcomes by comparing infants who receive the hepatitis B vaccine at birth against those who receive it at a later date. Under the trial design, half of the participating newborns would receive the birth dose immediately, while the other half would have their vaccination delayed for several weeks or months.
Ethical Concerns and Conflicting Claims
The study’s design has sparked significant criticism from global health researchers and infectious disease experts. Critics argue that withholding the standard birth dose of the hepatitis B vaccine from vulnerable infants lacks ethical justification, especially given that the vaccine has been used safely and effectively worldwide for decades to prevent vertical transmission of the virus.
Researchers leading the Bandim Health Project—Christine Stabell Benn and Peter Aaby—have defended the trial’s ethics, asserting that the study aligns with local standards of care in Guinea-Bissau, where a routine birth dose is not currently administered nationally but is officially slated for implementation by 2028. Proponents argue no participant is denied treatment they would otherwise routinely receive under current national guidelines.
Official Response and Status Uncertainty
The status of the project remains unclear following contradictory updates from international health bodies. Dr. Yap Boum of Africa CDC recently told media outlets that the controversial study had been called off, forwarding an undated letter from Guinea-Bissau’s health ministry suggesting a cancellation tied to the nation’s upcoming 2028 vaccination timeline.
However, the U.S. Department of Health and Human Services (HHS) and supporting organizations have pushed back against the cancellation reports, indicating that the research and funding remain active. As scientific oversight bodies, international organizations, and investigators continue to debate the study’s protocol, the future of the Guinea-Bissau newborn vaccination trial remains subject to ongoing administrative and ethical scrutiny.
